Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II RMPD regimen for newly diagnosed primary CNS lymphoma
ChiCTR2400093682Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Dec 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Complete response rate in the induced remission phase and Total response rate in the induced remission phase. Started Dec 2024; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2400093682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093682.